|Cancer Stem Cell News 7.13 April 4, 2018
Scientists isolated glioma stem cells from well-characterized glioblastoma patient-derived xenografts, characterized their stemness properties using immunofluorescence staining, profiled their epigenome including 5mC, 5hmC, 5fC/5caC, and two enhancer marks, and defined their transcriptome. [Genome Biol]
During tumorigenesis, de-differentiation of cherub-high cells lead to the formation of tumorigenic stem cells that accumulated abnormally high cherub levels. Investigators showed that cherub established a molecular link between the RNA-binding proteins Staufen and Syncrip. [eLife]
Researchers found that HOXB7 upregulated several canonical stem cell (SC)/induced pluripotent stem cell markers and sustained the expansion of a subpopulation of cells with SC characteristics, through modulation of LIN28B, an emerging cancer gene and pluripotency factor, which they discovered to be a direct target of HOXB7. [Oncogene]
Scientists used bioinformatics, immunohistochemistry, flow cytometry, spheroid self-renewal, and chemoresistance assays in combination with overexpression and siRNA-knockdown to study the stem cell-supportive role of doublecortin-like kinase 1 (DCLK1) alternative splice variants in renal cell carcinoma. [Int J Cancer]
Investigators showed that U-87 MG and D54 glioblastoma cell lines and multiple glioblastoma stem cell lines express transferrin receptors and that their growth is inhibited by gallium maltolate in vitro. [Mol Cancer Ther]
Researchers discovered that signaling between prostaglandin D2 (PGD2) and its receptor (PTGDR2) has the ability to restrict the self-renewal of gastric cancer cells in vitro and suppress tumor growth and metastasis in vivo. [Stem Cells]
The authors investigated Wnt-mediated carcinogenesis in pancreatic ductal adenocarcinoma (PDAC). They used the specific small molecule CBP/β-catenin antagonist, ICG-001, to examine its effects in human pancreatic cancer cells in both an orthotopic mouse model and a human patient-derived xenograft model of PDAC. [Cancers]
Scientists found that most breast cancer patient tissues resistant to tamoxifen were negative for CRB3 protein and positive for β-catenin protein, in contrast to their matched primary tumors by immunohistochemical analysis. [J Cell Mol Med]
Mechanistically, Toll-like receptor 4 promoted the expression of histone-lysine N-methyltransferase and increased the formation of trimethyl histone H3 lysine 9-heterochromatin protein 1-telomere repeat binding factor 2 complex at the telomeric locus under mediation by long non coding RNA urothelial cancer-associated 1. [J Cell Mol Med]
Ovarian clear cell carcinoma cell lines that were cultured in STK2, a serum-free medium for mesenchymal stem cells, or treated with TGF-β1 underwent morphological changes toward an epithelial-mesenchymal transition appearance, along with increased expression of left-right determination factor (LEFTY) and Snail. [Mol Carcinog]
Using expression profiling and CRISPR-interference assays with clinical samples of human liver cancers, investigators identified a long noncoding RNA, lncZic2, that is located near the Zic family member 2 locus and was highly expressed in liver cancer and liver tumor-initiating cells. [J Biol Chem]
The levels of colorectal CSCs markers were elevated in the tumorspheres cells. DATS efficiently suppressed the activity of colorectal CSCs, as evidenced by reducing the size and number of colonspheres, decreasing the expression of colorectal CSCs markers, promoting apoptosis and inhibiting the proliferation of colorectal CSCs. [Cancer Chemother Pharmacol]
The authors summarize the signaling pathways utilized by the EP (prostaglandin E receptor) family of G-protein-coupled receptor, their physiological and pathological roles in carcinogenesis, with special emphasis on the roles of EP4 in breast cancer progression. [Int J Mol Sci]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
AbbVie announced that after consulting with the FDA, it will not seek accelerated approval for Rova-T in third-line relapsed/refractory small cell lung cancer based on magnitude of effect across multiple parameters in this single-arm study. [AbbVie Inc.]
Cellectar Biosciences, Inc. announced that the United States Patent and Trademark Office has issued U.S. Patent No. P150207US03, entitled “Alkylphosphocholine analogs for multiple myeloma imaging and therapy”. [Cellectar Biosciences, Inc.]
PharmAbcine Inc. announced that FDA has granted orphan drug designation to its leading clinical compound TTAC-0001 for treatment of glioblastoma multiforme. [PharmAbcine Inc.]
AstraZeneca and MedImmune announced that the FDA has accepted the Biologics License Application for moxetumomab pasudotox, an investigational anti-CD22 recombinant immunotoxin and a potential new medicine for the treatment of adult patients with hairy cell leukemia who have received at least two prior lines of therapy. [AstraZeneca]
The March for Science has matured. It may even have outgrown its name. [ScienceInsider]
US government examines whether criteria for participating in drug studies unnecessarily exclude some people. [Nature News]
An influential committee of the European Parliament is due to vote on changes to copyright regulations in the European Union (EU), but the latest drafts of the rules have triggered a wave of criticism from open-science advocates. They say that the proposals will stifle research and scholarly communication. [Nature News]
NEW International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer
Visit our events page to see a complete list of events in the community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.